In conclusion, comprehensive analysis of cfDNA variants by targeted deep sequencing in HR+ HER2– BC cases not only confirmed the benefit of UMIs in the variant verification, but also identified new promising variants with clinical relevance for monitoring, prognosis, and therapy stratification. The gene discussed is ERBB2; the disease is breast cancer.